A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)
A study for patients with advanced hepatocellular carcinoma using study drug pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Enrolling: Male and Female Patients
IRB Number: AAAQ8401
U.S. Govt. ID: NCT02702414
Contact: Gulam Manji: 212-305-0592 / gam2140@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety, tolerability, and anti-tumor activity of the research study drug, Pembrolizumab (also known as MK-3475) in subjects with advanced hepatocellular carcinoma (a type of liver cancer also referred to as HCC) who have taken sorafenib.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Have you been diagnosed with advanced hepatocellular carcinoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Gulam Manji
gam2140@cumc.columbia.edu
212-305-0592
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE